Fulcrum Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 97.34 million compared to USD 109.87 million a year ago. Basic loss per share from continuing operations was USD 1.59 compared to USD 2.44 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.56 USD | +2.86% | +0.80% | +12.59% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.59% | 457M | |
+29.67% | 48.16B | |
-1.20% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+9.88% | 25.59B | |
-22.99% | 18.96B | |
+8.42% | 12.92B | |
+28.92% | 12.03B | |
-2.08% | 11.77B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023